EC-352H / Eone Diagnomics Genome Center - LARVOL DELTA

Anti-cancer effects of HDAC8 specific inhibitors EC-352H and EC-374H in lymphoma (ESMO 2023) - "Conclusions EC-352H and EC-374H, novel HDAC8 specific inhibitors, act as anticancer agents and inhibit lymphoma. These can be potential alternatives for overcoming disadvantages of conventional HDAC inhibitors by enhancing HDAC8 selectivity."

Hematological Malignancies • Lymphoma • Oncology • CASP3

K-Bio to participate in ESMO2023… Latest cancer treatment and diagnosis technology unveiled in Europe [Google translation] (E-Today) - "In addition, EDGC (Eone Diagnomics) plans to disclose the efficacy of its anticancer drug candidates 'EC-352H' and 'EC-374H' on lymphatic cancer, and SillaJen announced the results of a study on Pexa-Vec and Libtayo combination therapy for kidney cancer and 'BAL0891' research overview."

Clinical data • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor